[Event Report] Roundtable – Preparatory Meeting: The Management Structure and FY2019 Activities of AMR Alliance Japan (March 19, 2019)
date : 4/12/2019
Tags: AMR
![[Event Report] Roundtable – Preparatory Meeting: The Management Structure and FY2019 Activities of AMR Alliance Japan (March 19, 2019)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-3top.jpg)
Every year, Antimicrobial Resistance (AMR) kills approximately 700,000 people globally. In Japan, AMR has become a major challenge for many medical facilities, with cases of community-acquired drug-resistant infections on the rise nationally. To combat this issue, Japan enacted a National Action Plan on Antimicrobial Resistance in April 2016.
Sensing the growing concern about AMR domestically and abroad, HGPI has taken the initiative to host multiple expert meetings on this subject since 2016. Over the course of those expert meetings, it was suggested that the establishment of an independent platform for multi-stakeholder discussion on AMR was needed to encourage more impactful collaborations on the AMR policies.
To that end, in November 2018, HGPI joined together with eight Japanese medical societies involved with infectious disease medicine to establish AMR Alliance Japan, a multi-stakeholder, collaborative body that will work to improve public health by promoting AMR countermeasures.
During this preparatory meeting, representatives of participating academic societies and FY2018 project sponsors came together to discuss the management structure of AMR Alliance Japan and the actions to be carried out by the Alliance in FY2019.
Organizer: HGPI
Participants: AMR Alliance Japan academic society members and corporate stakeholders
Opening (explanatory introduction)
Matt McEnany (Manager, Health and Global Policy Institute)
Roundtable Discussion
Roundtable Speakers (alphabetical order by last name)
Yusuke Ariyoshi (Director, Healthcare Policy, Government Affairs Dept., Shionogi & Co., Ltd.)
Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)
Shinya Nagase (Director, Diagnostic Systems, BD Life Sciences, Nippon Becton Dickinson Company, Ltd.)
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute)
Masahiro Okuda (President, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Faculty of Medicine, Mie University Graduate School)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Yoshinobu Takakura (Vice President, Candidate for President, The Pharmaceutical Society of Japan, / Professor, Graduate School of Pharmaceutical Sciences, Kyoto University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control / Professor, Department of Infectious Disease and Infection Control, The Jikei University School of Medicine)
Top Research & Recommendations Posts
- [Policy Recommendation] Preparing for “Disaster-Level Heat” in the 2025 Basic Policy on Economic and Fiscal Management and Reform (June 9, 2025)
- [Policy Recommendation] Integrating “Planetary Health” as a Growth Strategy — Proposal for the Grand Design and Action Plan for a New Form of Capitalism (2025 Revised Edition) (June 9, 2025)
- [Event Report] Round Table Discussion “Understanding Menopausal Women’s Health as a Social Issue” (November 19, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] HGPI Joint Input to the Zero Draft Political Declaration on NCDs and Mental Health (May 23, 2025)
- [Policy Recommendations] Achieving a Sustainable Society of Health and Longevity Through the Integration of Environment and Healthcare-Incorporating a Planetary Health Perspective into the 3rd Phase of The Healthcare Policy-(December 20, 2024)
Featured Posts
-
2025-07-04
[Registration Open] (Webinar) The 136th HGPI Seminar “Where We Are Now and Where We Are Going Regarding PPI in Mental Health Research: Learning from the TOGETHER Project in the Form of Co-Creation” (July 28, 2025)
-
2025-07-04
[Event Report] The HGPI Cardiovascular Disease (CVD) Control Promotion Project Online Global Symposium “Exploring the Future of CVD Control Through Policy Case Studies in the Asia-Pacific Region” (March 13, 2025)
-
2025-07-04
[HGPI Policy Column] (No. 62) From the Dementia Project “The Current State of Dementia Policy in the International Community in 2025”
-
2025-07-04
[Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)